In this highlight video from the March 2024 AD symposium, Dr. Lawrence Eichenfield discusses the relationship between skin barrier dysfunction and the potential for increased risk of allergic sensitization. He goes on to discuss the high proportion of pediatric patients with AD who exhibit at least 1 atopic comorbidity.
Vice Chair of the Department of Dermatology | University of California San Diego (UCSD) School of Medicine; Chief of Pediatric and Adolescent Dermatology | Rady Children’s Hospital San Diego, California, United States
See author’s profileADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.
© 2024 Sanofi and Regeneron Pharmaceuticals, Inc.
All rights reserved.
MAT-GLB-2302957 v3.0 11/2023
All Rights Reserved.
Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.